3,750,000 Common Shares TEKMIRA PHARMACEUTICALS CORPORATION (incorporated under the Business Corporations Act (British Columbia)) UNDERWRITING AGREEMENTUnderwriting Agreement • March 13th, 2015 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • New York
Tekmira Pharmaceuticals Corporation, a company incorporated under the Business Corporations Act (British Columbia) (the "Company"), proposes to sell to the several underwriters (the "Underwriters") named in Schedule I hereto for whom Stifel Nicolaus & Company, Incorporated is acting as representative (the "Representative"), an aggregate of 3,750,000 common shares (the "Firm Shares") of the Company (the "Common Shares"). The Company has also granted to the several Underwriters an option to purchase up to an aggregate of 562,500 additional Common Shares, on the terms and for the purposes set forth in Section 3 hereof (the "Option Shares"). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the "Securities."
MANUFACTURING AND CLINICAL TRIAL AGREEMENT BETWEEN THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD AND TEKMIRA PHARMACEUTICALS CORPORATION ON BEHALF OF ITSELF AND ITS WHOLLY OWNED AFFILIATE, PROTIVA BIOTHERAPEUTICS INC. DATED DECEMBER...Manufacturing and Clinical Trial Agreement • March 13th, 2015 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • England and Wales
This MANUFACTURING AND CLINICAL TRIAL AGREEMENT is made as of this 18th day of December, 2014) (the “Effective Date”) between Tekmira Pharmaceuticals Corporation, on behalf of itself and its wholly owned Affiliate, Protiva Biotherapeutics, Inc. (collectively “Tekmira”), each a B.C. corporation having its principal place of business at 100-8900 Glenlyon Way, Burnaby, B.C.V5J 5J8, Canada, and The Chancellor Masters and Scholars of the University of Oxford (“OXFORD”) whose administrative address is University Offices, Wellington Square, Oxford, OX1 2JD.
LICENSE AGREEMENT by and between DICERNA PHARMACEUTICALS, INC., on the one hand, and PROTIVA BIOTHERAPEUTICS INC. and TEKMIRA PHARMACEUTICALS CORPORATION on the other hand Dated: November 16, 2014License Agreement • March 13th, 2015 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • New York
This LICENSE AGREEMENT (this “Agreement”) is entered into as of November 16, 2014 (the “Effective Date”), by and between Dicerna Pharmaceuticals, Inc., a Delaware corporation with offices at 480 Arsenal Street, Building 1, Suite 120, Watertown, MA 02472 USA and its Affiliates (“Dicerna”), on the one hand, and Protiva Biotherapeutics Inc., a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Protiva”), and Tekmira Pharmaceuticals Corporation, a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Tekmira”), on the other hand.
EMPLOYMENT AGREEMENTEmployment Agreement • March 13th, 2015 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • British Columbia
TEKMIRA PHARMACEUTICALS CORPORATION, a company incorporated under the laws of British Columbia (the "Company"), with offices at 100 - 8900 Glenlyon Parkway, Burnaby, British Columbia fax: (604) 419-3201
EXECUTIVE EMPLOYMENTAGREEMENTExecutive Employmentagreement • March 13th, 2015 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • Washington
2,125,000 Common Shares TEKMIRA PHARMACEUTICALS CORPORATION (incorporated under the Business Corporations Act (British Columbia)) UNDERWRITING AGREEMENTTEKMIRA PHARMACEUTICALS Corp • March 13th, 2015 • Pharmaceutical preparations • New York
Tekmira Pharmaceuticals Corporation, a company incorporated under the Business Corporations Act (British Columbia) (the "Company'), proposes to sell to Leerink Partners LLC (the 1'Underwriter"), an aggregate of 2,125,000 common shares (the "FirmShares") of the Company (the "Common Shares"). The Company has also granted to the Underwriter an option to purchase up to an aggregate of 318,750 additional Common Shares, on the terms a11d for the purposes set forth in Section 3 hereof (the "Option Shares"). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the "Securities."
